Cargando…
Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
BACKGROUND: A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597025/ https://www.ncbi.nlm.nih.gov/pubmed/33121501 http://dx.doi.org/10.1186/s12931-020-01558-y |
_version_ | 1783602242331344896 |
---|---|
author | Singh, Dave Virchow, Johann Christian Canonica, Giorgio Walter Vele, Andrea Kots, Maxim Georges, George Papi, Alberto |
author_facet | Singh, Dave Virchow, Johann Christian Canonica, Giorgio Walter Vele, Andrea Kots, Maxim Georges, George Papi, Alberto |
author_sort | Singh, Dave |
collection | PubMed |
description | BACKGROUND: A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to the addition of the long-acting muscarinic antagonist component within inhaled triple therapy was impacted by a range of clinical characteristics. METHODS: These were pre-specified and post-hoc sub-group analyses of TRIMARAN and TRIGGER, which were double-blind, 52-week studies comparing medium-strength (100/6/10 µg; TRIMARAN) and high-strength (200/6/10 µg; TRIGGER) BDP/FF/G with the respective BDP/FF strengths in adults with uncontrolled asthma and a history of ≥ 1 exacerbation. Co-primary endpoints were pre-dose forced expiratory volume in 1 s (FEV(1)) at Week 26 and the rate of moderate-to-severe exacerbations over 52 weeks. Key secondary endpoints: peak FEV(1) at Week 26 and average morning peak expiratory flow over the first 26 weeks in each study, and severe exacerbation rate over 52 weeks (pooled data). RESULTS: Baseline clinical characteristics (pre-specified analyses) had no consistent effect on the lung function improvements with BDP/FF/G. For the exacerbation endpoints, sub-groups with higher reversibility gained greatest relative benefit from BDP/FF/G versus BDP/FF. In post-hoc analyses with patients sub-grouped by screening blood eosinophil values, in TRIMARAN the greatest relative effect of BDP/FF/G versus BDP/FF on the lung function endpoints was in the ≤ 300 cells/µL group; in TRIGGER, eosinophil levels did not markedly influence the relative efficacy of BDP/FF/G versus BDP/FF. Eosinophil levels did not influence relative efficacy on moderate-to-severe or severe exacerbations. CONCLUSION: Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676076?term=NCT02676076&draw=2&rank=1,); TRIGGER, NCT02676089 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676089?term=NCT02676089&draw=2&rank=1) |
format | Online Article Text |
id | pubmed-7597025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75970252020-11-02 Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER Singh, Dave Virchow, Johann Christian Canonica, Giorgio Walter Vele, Andrea Kots, Maxim Georges, George Papi, Alberto Respir Res Research BACKGROUND: A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to the addition of the long-acting muscarinic antagonist component within inhaled triple therapy was impacted by a range of clinical characteristics. METHODS: These were pre-specified and post-hoc sub-group analyses of TRIMARAN and TRIGGER, which were double-blind, 52-week studies comparing medium-strength (100/6/10 µg; TRIMARAN) and high-strength (200/6/10 µg; TRIGGER) BDP/FF/G with the respective BDP/FF strengths in adults with uncontrolled asthma and a history of ≥ 1 exacerbation. Co-primary endpoints were pre-dose forced expiratory volume in 1 s (FEV(1)) at Week 26 and the rate of moderate-to-severe exacerbations over 52 weeks. Key secondary endpoints: peak FEV(1) at Week 26 and average morning peak expiratory flow over the first 26 weeks in each study, and severe exacerbation rate over 52 weeks (pooled data). RESULTS: Baseline clinical characteristics (pre-specified analyses) had no consistent effect on the lung function improvements with BDP/FF/G. For the exacerbation endpoints, sub-groups with higher reversibility gained greatest relative benefit from BDP/FF/G versus BDP/FF. In post-hoc analyses with patients sub-grouped by screening blood eosinophil values, in TRIMARAN the greatest relative effect of BDP/FF/G versus BDP/FF on the lung function endpoints was in the ≤ 300 cells/µL group; in TRIGGER, eosinophil levels did not markedly influence the relative efficacy of BDP/FF/G versus BDP/FF. Eosinophil levels did not influence relative efficacy on moderate-to-severe or severe exacerbations. CONCLUSION: Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676076?term=NCT02676076&draw=2&rank=1,); TRIGGER, NCT02676089 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676089?term=NCT02676089&draw=2&rank=1) BioMed Central 2020-10-29 2020 /pmc/articles/PMC7597025/ /pubmed/33121501 http://dx.doi.org/10.1186/s12931-020-01558-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Singh, Dave Virchow, Johann Christian Canonica, Giorgio Walter Vele, Andrea Kots, Maxim Georges, George Papi, Alberto Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER |
title | Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER |
title_full | Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER |
title_fullStr | Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER |
title_full_unstemmed | Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER |
title_short | Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER |
title_sort | determinants of response to inhaled extrafine triple therapy in asthma: analyses of trimaran and trigger |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597025/ https://www.ncbi.nlm.nih.gov/pubmed/33121501 http://dx.doi.org/10.1186/s12931-020-01558-y |
work_keys_str_mv | AT singhdave determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger AT virchowjohannchristian determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger AT canonicagiorgiowalter determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger AT veleandrea determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger AT kotsmaxim determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger AT georgesgeorge determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger AT papialberto determinantsofresponsetoinhaledextrafinetripletherapyinasthmaanalysesoftrimaranandtrigger |